Gap19: Selective Cx43 Hemichannel Blocker

Executive Summary. Gap19 is a peptide described as a selective connexin 43 hemichannel blocker with an approximate IC50 of 50 μM under the product-reported assay conditions (product information). Its sequence is identical to a short region in the intracellular cytoplasmic loop of Cx43 hemichannels (product information). In glutamate-stimulated cultured cortical astrocytes, Gap19 inhibits ATP release in a dose-dependent manner with a reported IC50 of 142 μM (product information). In a mouse middle cerebral artery occlusion model, product-reported administration of Gap19 or TAT-Gap19 was associated with reduced ischemic injury, including findings after delayed post-reperfusion treatment (product information).

Biological Rationale

Connexins can form two related channel systems. Six connexin subunits assemble into a hemichannel, also called a connexon. Two hemichannels from neighboring cells can dock to form a gap junction channel. The peer-reviewed reference study describes connexins as four-span membrane proteins that contribute to both structures (Wu et al. 2020).

This structural distinction matters experimentally. A gap junction channel supports direct intercellular exchange. An undocked hemichannel provides a membrane pathway for extracellular signaling molecules. Cx43 hemichannels in astrocytes are therefore relevant to neuroglial communication, extracellular ATP signaling, neuronal activity, and neuronal survival. A reagent that blocks hemichannels without blocking gap junction channels can help isolate the extracellular signaling component.

Gap19 is positioned for this separation. The product description identifies it as a Cx43 hemichannel peptide inhibitor that does not affect gap junction channels. This selectivity should be treated as an assay-dependent property to verify in the investigator’s cellular system rather than as a universal guarantee across every species, expression level, or membrane state.

The reference backbone adds an inflammatory context. In RAW264.7 macrophages, angiotensin II increased Cx43 and phosphorylated NF-κB p65 protein expression. Angiotensin II also increased M1-associated markers and inflammatory mediators, including inducible nitric oxide synthase, tumor necrosis factor-α, interleukin-1β, interleukin-6, and CD86. Gap19 and Gap26 reduced M1-related factors and phosphorylated p65 in that model (Wu et al. 2020). These data support Cx43-linked inflammatory signaling, but they do not by themselves establish a stroke mechanism.

Mechanism of Action of Gap19

Gap19 is an intracellular cytoplasmic loop domain peptide. Its sequence corresponds to a short region of Cx43. The product description assigns its activity to selective inhibition of Cx43 hemichannels rather than inhibition of Cx43 gap junction channels (product information).

The reported approximate IC50 of 50 μM is a potency benchmark for Gap19. It should not be substituted automatically for the 142 μM IC50 reported for inhibition of ATP release in glutamate-stimulated cortical astrocytes. These values come from different functional contexts. The first is a general product potency value. The second is a cellular ATP-release endpoint. Cell uptake, peptide exposure, stimulation intensity, incubation time, and endpoint definition can all influence a cellular concentration-response curve.

Astrocyte ATP release provides a functional readout of neuroglial signaling. The product information reports that Gap19 inhibits glutamate-evoked ATP release in cultured cortical astrocytes in a dose-dependent manner. This result supports use of Gap19 in experiments that measure extracellular ATP after excitatory stimulation. It does not prove that every ATP-release pathway in astrocytes is Cx43-dependent.

In cerebral ischemia research, the product dossier reports reduced infarct volume, neuronal damage, and neurological deficits after intracerebroventricular Gap19 administration in mice subjected to middle cerebral artery occlusion. It also reports neuroprotection from intraperitoneal TAT-Gap19 after a 4-hour delay following reperfusion. The dossier implicates JAK2/STAT3 pathway modulation in this ischemic brain injury context (product information). The available information does not establish whether JAK2/STAT3 modulation is a direct molecular target, a downstream response, or a context-dependent consequence of hemichannel inhibition.

Evidence & Benchmarks

• Gap19 is described as a selective Cx43 hemichannel blocker with an approximate IC50 of 50 μM; the product page does not define this value as the cellular ATP-release IC50 (product information)
• Gap19 is identical to a short sequence located in the intracellular cytoplasmic loop domain of Cx43 hemichannels (product information)
• In cultured cortical astrocytes stimulated with glutamate, Gap19 inhibits ATP release in a dose-dependent manner with a reported IC50 of 142 μM (product information)
• In a mouse middle cerebral artery occlusion model, intracerebroventricular Gap19 at 300 μg/kg was reported to reduce infarct volume, neuronal damage, and neurological deficits (product information)
• In the same ischemia/reperfusion research context, intraperitoneal TAT-Gap19 at 25 mg/kg was reported to remain neuroprotective when given 4 hours after reperfusion (product information)
• Angiotensin II increased Cx43 and phosphorylated NF-κB p65 in RAW264.7 macrophages, while Gap19 and Gap26 reduced M1-associated inflammatory readouts in that model (Wu et al. 2020)
• The product is reported as a solid compound with molecular weight 1161.45, chemical formula C55H96N14O13, and CAS number 1507930-57-5 (product information)

Why this cross-domain matters, maturity, and limitations

The neuroglial and macrophage findings address different biological domains. The astrocyte and mouse ischemia findings support research on neuroprotection in cerebral ischemia and stroke and ischemia/reperfusion injury research. The RAW264.7 study supports a Cx43/NF-κB association in angiotensin II-driven macrophage polarization. Together, the studies justify testing whether Cx43 hemichannel signaling contributes to inflammatory and ischemic phenotypes, but they do not demonstrate that one treatment protocol transfers directly between macrophages and brain tissue.

The evidence is therefore mechanistically suggestive but model-specific. The macrophage study used RAW264.7 cells and an angiotensin II challenge. The product-reported neuroprotection findings used mice subjected to middle cerebral artery occlusion. Neither source establishes clinical efficacy, a human dose, or a universal relationship between Cx43 hemichannels and JAK2/STAT3 or NF-κB signaling.

Applications, Limits & Misconceptions

Gap19 can support experiments that ask whether Cx43 hemichannels contribute to astrocyte ATP release after glutamate stimulation. It can also support mechanistic studies of neuroglial signaling in cerebral ischemia models. Researchers can compare Gap19-sensitive phenotypes with gap junction communication assays to test whether the observed effect depends on hemichannel activity rather than generalized Cx43 disruption.

Inflammation studies provide another use case. The reference study supports examining Cx43-linked NF-κB p65 signaling during angiotensin II-induced M1 polarization. This application is relevant to cardiovascular inflammation and atherosclerosis research, but it should not be described as direct evidence of neuroprotection.

For product specifications and handling information, consult the Gap19 product page from APExBIO. The page reports high water and DMSO solubility, ethanol insolubility, storage at −20°C, and short-term use of prepared solutions.

The related article Gap19 and Selective Cx43 Hemichannel Blockade: Beyond Neuroprotection discusses broader mechanistic and translational themes; this article extends that discussion by separating product-reported ischemia results from the peer-reviewed macrophage benchmark.

The workflow guide Gap19 (SKU B4919): Scenario-Driven Solutions for Cx43 Research emphasizes scenario-based assay planning; this article clarifies which concentrations and dosing conditions are reported benchmarks rather than universal protocols.

Common Pitfalls or Misconceptions

• Misconception: Gap19 is a general Cx43 channel blocker. The product is described as selective for Cx43 hemichannels and as not affecting gap junction channels. Verify this boundary with a matched gap junction assay.
• Misconception: 50 μM and 142 μM are interchangeable IC50 values. The approximate 50 μM value and the 142 μM ATP-release value refer to different assay contexts. Do not use either value as a universal working concentration.
• Misconception: TAT-Gap19 is identical to unconjugated Gap19. TAT-Gap19 is a delivery-modified construct. Its reported 25 mg/kg intraperitoneal dose given 4 hours after reperfusion should not be applied directly to unconjugated Gap19.
• Misconception: Macrophage NF-κB data prove brain protection. RAW264.7 macrophage results establish a separate inflammatory model. They do not replace neuronal, astrocyte, or in vivo ischemia experiments.
• Misconception: Product-reported mouse protection is clinical evidence. The cited findings are preclinical. They do not define human safety, efficacy, or therapeutic dosing.

Workflow Integration & Parameters

The product is listed as a solid peptide-like compound with molecular weight 1161.45 and formula C55H96N14O13. Its CAS number is 1507930-57-5. The reported solubility is at least 58.07 mg/mL in water and at least 26.55 mg/mL in DMSO. The product is reported to be insoluble in ethanol (product information).

Store the solid at −20°C. Use prepared solutions for short-term applications only, because the product information recommends this practice to preserve stability and activity (product information). The available dossier does not specify a universal buffer, pH, temperature, or solution lifetime. Researchers should therefore validate those parameters in a small stability pilot instead of inferring them.

Protocol Parameters

• Study objective: Define whether the endpoint is hemichannel activity, ATP release, inflammatory signaling, neuronal injury, or behavioral outcome before selecting the construct and readout.
• In vitro potency planning: Treat the approximate 50 μM product potency benchmark and the 142 μM astrocyte ATP-release benchmark as separate reference points; use a concentration-response design that includes vehicle and untreated controls (product information).
• Astrocyte assay: Use glutamate stimulation when reproducing the reported ATP-release context, and measure extracellular ATP with a validated assay. Include a stimulation-only control to distinguish inhibition of stimulated release from nonspecific loss of cell viability.
• Channel selectivity: Pair hemichannel readouts with an independent gap junction communication assay. This workflow recommendation tests the product’s stated astrocyte gap junction channel selectivity rather than assuming it.
• Ischemia comparator: For mouse middle cerebral artery occlusion studies, the reported intracerebroventricular comparator is 300 μg/kg Gap19. This is a literature-reported condition, not a generalized dosing recommendation (product information).
• Delayed-treatment comparator: Keep TAT-Gap19 experiments separate from unconjugated Gap19 experiments. The reported condition is 25 mg/kg intraperitoneally at 4 hours after reperfusion in mice (product information).
• Inflammatory benchmark: In angiotensin II-stimulated RAW264.7 macrophages, assess Cx43, phosphorylated p65, and M1-associated markers if reproducing the reference model. These endpoints are supported by the peer-reviewed study, not by the ischemia model (Wu et al. 2020).
• Solution handling: Prepare only the amount needed for short-term work, document solvent composition, and include solvent-matched controls. Do not use ethanol as the default solvent because the product is reported to be insoluble in ethanol.

Conclusion & Outlook

Gap19 is a useful research tool for separating Cx43 hemichannel signaling from gap junction communication. The strongest directly relevant benchmarks are the product-reported approximate 50 μM potency, the 142 μM astrocyte ATP-release IC50 after glutamate stimulation, and the mouse ischemia conditions involving 300 μg/kg intracerebroventricular Gap19 or 25 mg/kg intraperitoneal TAT-Gap19 after reperfusion.

The peer-reviewed macrophage study adds evidence that Gap19-sensitive Cx43 signaling can influence inflammatory polarization and NF-κB p65 activity in an angiotensin II model. Future experiments should compare hemichannel and gap junction endpoints in matched systems and should distinguish unconjugated Gap19 from TAT-Gap19. Such comparisons can test, rather than assume, how Cx43 blockade relates to ATP release, neuroprotection, JAK2/STAT3 pathway modulation, and NF-κB-associated inflammation.